Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elsubrutinib - AbbVie

Next Previous
Drug Profile

Elsubrutinib - AbbVie

Alternative Names: ABBV-105

Latest Information Update: 29 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AbbVie
  • Class Anti-inflammatories; Antirheumatics; Indoles; Piperidines; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 11 Jun 2025 Efficacy data from a phase II trial in Systemic lupus erythematosus presented at the 26th Annual Congress of the European League Against Rheumatism (EULAR-2025)
  • 12 Jun 2024 Efficacy data from the phase-II SLEek trial in Systemic lupus erythematosus presented at the 25th Annual Congress of the European League Against Rheumatism (EULAR-2024)
  • 03 Jan 2024 AbbVie completes a phase II trial in Systemic lupus erythematosus (Combination therapy, In adults) in Argentina, Australia, Bulgaria, Colombia, China, Germany, Hungary, Japan, Italy, Mexico, South Korea, New Zealand, Poland, Puerto Rico, Spain, Taiwan, United Kingdom and USA (PO) (NCT04451772)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top